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Trends
There is increasing demand for syn-
thetic alternatives to a patient's own
material in regenerative strategies for
damaged or diseased tissues and
organs. In bone regeneration, CaPs
are promising candidates.
While traditional CaP designs were
focused on the initiation and guidance
of new bone formation, the next gen-
eration of CaP materials needs to bet-
ter address the complexity of the bone-
healing environment.
Successful CaP bone-graft substitutes
for clinically relevant bone defects must
be able to establish and maintain
proper vasculature.
Instead of adding cells or growth fac-
tors to establish both angiogenesis and
bone growth, the focus is now on inor-
ganic or small molecules, and on the
improved design of CaPs. These prio-
rities aim to enhance the clinical perfor-
mance and affordability of CaPs.
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Calcium phosphates (CaPs) are among the most utilized synthetic biomaterials
for bone regeneration, largely owing to their established osteoconductive and
osteoinductive properties. While angiogenesis is a crucial prerequisite to bone
formation, research and applications for CaPs have not appreciated its crucial
role. This review discusses how CaPs influence angiogenesis, and highlights
promising strategies that address this topic. The objective is to draw attention to
the gap in the literature and to highlight the importance of angiogenesis in CaP
research, development, and use.
Why Consider Angiogenesis in CaP-Augmented Bone Regeneration?
Traditionally, three components guide bone tissue engineering (see Glossary): osteoconduc-
tivity, osteoinductivity, and osseointegration [1,2]. With a long history of development, CaPs fulfill
two of these criteria: they are commercially available as osteoconductive bone-graft substitutes
and have demonstrated osteoinductive potential [3–5]. One of the most relevant features of CaPs
is their chemical similarity to the inorganic phase of bone matrix [6], providing a rationale for their
use. Over decades, extensive research on CaP-based materials has aimed to improve their
potential for osteogenesis-related processes; however, these efforts have not focused on how
CaPs influence angiogenesis, despite it being a crucial process for bone formation.
Vascularization is vital for bone defects to heal, which in turn facilitates the development of actual
osteoid deposition and matrix development within normal bone healing. Importantly, a coupling
link exists between the angiogenic and osteogenic cells and signals, underscoring the
importance of these interactions (Box 1). In practice, there is a greater need for vascularization
at sites where bone graft substitutes are used because they are larger, more complex environ-
ments, and require more control in tissue formation and development. Tissue engineering
approaches generally employ a classical three-way focus on osteoconduction, osteoinduc-
tion, and osteogenesis. By contrast, the more clinically relevant so-called diamond concept
acknowledges the complexity of the bone niche by considering the vasculature and the
mechanical environment [7]. This concept, together with deeper insights into the coupling of
healing mechanisms, highlights the oversight and misalignment of CaP research and develop-
ment, and supports a greater consideration for angiogenesis in related CaP research. In
developing bone-graft substitutes that take into account the importance of angiogenesis, a
wealth of information can be obtained from other fields (Box 2).
Bone healing is a complex process that consists of various overlapping phases with many
cellular and molecular processes or requirements [8]. Complications in this process, such asTrends in Biotechnology, December 2016, Vol. 34, No. 12 http://dx.doi.org/10.1016/j.tibtech.2016.07.005 983
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Glossary
Angiogenesis: the process and
stimulation of new blood vessel
formation via sprouting from existing
blood vessels.
Bioinorganics: inorganic elements
that are often naturally occurring
within the body in trace quantities,
and which can stimulate and
influence a wide range of cellular
processes.
Bone tissue engineering: the three
components traditionally considered
to be essential are osteoconductive
biomaterials such as calcium
phosphates (CaPs), osteoinductive
signals such as growth factors, and
bone-forming cells such osteogenic
cells and mesenchymal stem cells.
Delayed healings and non-unions:
the extensive formation of
fibrocartilage across a bone defect
site leads to healing complications,
which may be more likely with
increasing soft tissue and vascular
damage. No consensus exists in how
to classify these events, although it is
sometimes considered to be > 3
months for delayed healings and > 9
months for non-unions.
Diamond concept: a broad concept
in bone healing that builds on the
three components of bone tissue
engineering to include the mechanical
environment and the vasculature, as
well as considering the biological
variations of the host system.
Osteogenic cells: cells that are
related to bone formation, such as
osteoprogenitors, preosteoblasts,
bone-lining cells, and osteoblasts.
Osteoconduction: the ability of the
material to facilitate the attachment of
osteoprogenitor cells, necessary for
Box 1. Cells and Signals Relevant to Blood Vessels Within Bone
Blood vessels transport oxygen, nutrients, and waste, and they also act as a passageway for immune system
components, cell-signaling molecules, and cells [79–81]. Endothelial cells (ECs) form the capillary tubes where compo-
nent transfer occurs [82], and these connect the circulatory loop of arteries and veins. Vascular smooth muscle cells
(VSMCs) and pericytes form the arterial and venous vessels, and regulate EC proliferation via cell contact and paracrine
signaling [78,83]. EC proliferation and lateral migration are the major source of new ECs, although the progenitors are
predominantly bone marrow–derived [84].
Many signaling molecules are involved in angiogenesis, of which vascular endothelial growth factor (VEGF) and basic
fibroblast growth factor (bFGF) are the most prominent. VEGF and bFGF exert chemotactic and mitogenic functions by
binding to their associated receptors on ECs, inducing the release of matrix metalloproteinases (MMP) that degrade
components of the extracellular matrix. Proliferating and migrating ECs sprout into this newly formed space, forming new
blood vessels, while tissue inhibitors of metalloproteinases (TIMPs) regulate MMP activity [85].
Sprouting ECs can be differentiated by their position and function into tip and stalk ECs. Both tip and stalk ECs are
controlled by Notch signaling pathways, with tip cells expressing Notch ligand DLL4 and stalk cells having high Notch
expression. Tip cells sprout vessels according to optimal oxygen delivery, while stalk cells form the basement membrane
components that form the lumen of the vessels. Complex interactions exist between VEGF receptors, Notch and DLL4
signaling, and feedback loops [79]. Recently, a specific subpopulation of ECs was described, defined as type H ECs,
which more strongly express CD31 and endomucin cell-surface markers compared to type L ECs. Osteoprogenitors,
expressing Runx2 and Osterix, indicative of osteoblastic precursors, were located directly around type H vessels [80].
This type H subpopulation also secretes noggin, a bone morphogenetic protein antagonist, but sustainer of osteoblasts.
These osteoblasts in turn secrete VEGF, coupling angiogenesis and osteogenesis mechanisms [81]. Such bone
microvessel type H ECs are regulated by HIF-1/ and DLL4–Notch signaling mechanisms [80], and are an interesting
differentiator of EC subtypes relevant to bone regeneration and targets for CaPs.delayed healings and non-unions, are often attributed to a failure in restoring vasculature,
and not to a lack of osteogenic potential [9]. Bone-graft substitutes are often needed under
circumstances of increased risk, but without the prerequisite blood supply, the healing envi-
ronment struggles to even reach the phase when osteogenesis is required. Further, CaP
implantation from time-zero aligns with the phase related to hematoma formation and inflam-
mation; although osteogenic differentiation is not yet a concern, it should not be neglected.
To understand bone formation at a systems level, researchers must consider endothelial cells
(ECs), osteoblasts, and their innate linkage. Preosteoblasts are recruited and maintained by
interaction with ECs, ensuring suitable migration to the place of need [10]. When considering
CaP use within a bone defect, a functioning capillary network provides a migration pathway for
endogenous cells [11], and this pathway is crucial for delivering osteoprogenitor cells to the often
otherwise cell-free CaP scaffold. Therefore, the coupling of osteogenesis and angiogenesis isbone formation on or throughout the
material.
Osteoinduction: the stimulation of
undifferentiated and multipotent cells
towards osteoblasts capable of
depositing bone matrix.
Proangiogenic factors: any
substance capable of stimulating
angiogenesis, of which bFGF and
VEGF are most commonly
considered, although many cofactors
and crosstalk can exist.
Box 2. Lessons Learned from the Oncology Field
Considerable knowledge about angiogenesis has been established within tumor progression and metastasis research,
where limiting angiogenesis is crucial in suppressing tumor development. Within this realm, angiogenesis is considered to
be a highly regulated process, switching on for days, followed by inhibition, as evident with angiogenic phenotype
activation of tumor cells in tumor development and growth [86]. Despite the cell densities, ECs are most often quiescent,
with only 0.01% dividing at any time [87]. In relation to bone healing, there is great potential in activating proliferation
temporally, capturing the angiogenic switching window of the bone-healing environment at the early stages of healing,
and limiting any stagnant cell populations. For tumor control, antiangiogenic agents are deployed, such as VEGF
inhibitors, whose goal is to limit EC proliferation to prevent vessel growth, to promote EC death, and to suppress the
mobilization of progenitor ECs from the bone marrow [82]. Hence, stimulating vessel regeneration for bone healing
requires suitable signaling to induce EC migration and proliferation, and focus on these mechanisms is a justified aim.
Another interesting approach is the inhibition of specific signaling pathways. While VEGF signaling is known to be
essential for bone healing, halting angiogenesis in disease and disorders using VEGF inhibition alone is considered
insufficient owing to associated upregulation of complementary factors [82]. This suggests that single-mechanism
strategies may be limited because their effects may be compensated by the downregulation of other processes. In
addition, the importance of a single angiogenic factor does not imply that supraphysiological levels will actually be
beneficial.





Figure 1. (A) Osteoblasts (Triangles) Line the Surface of a Pore of the Calcium Phosphate (CaP) with
Endothelial Cells (Arrows) on a Hematoxylin/Eosin/Safranin Stained Section (1000). Pore dimensions can
influence vessel formation and blood supply to the osteoblasts, and thus bone formation. Reproduced, with permission,
from Henno et al. [88]. (B) Capillaries (arrows), highlighted with von Willebrand factor immunostaining, demonstrate the
penetration of vessels into a CaP-based product embedded in a SiO2 (NovaBone
®, NB), surrounded by new bone (B).
Reproduced, with permission, from Götz, et al. [12].essential in the bone-healing environment [12] (Figure 1). Furthermore, the close connection of
blood vessels and bone cells maintains skeletal integrity, an underappreciated relationship in
CaP development. This review discusses current and potential strategies to improve the
angiogenic response when CaPs are used for the augmentation of bone defects. Such
information could help to shape a new generation of CaP bone-graft substitutes that more
effectively and relevantly address the needs of the regenerating bone system.
What are the Roles and Relevant Effects of CaP Material?
The physiological importance of both calcium [13–15] and phosphate [16–18] has been well
described. Calcium and phosphate are regulated throughout the body via a homeostatic
pathway, the vasculature. While calcium and phosphate are crucial for homeostasis, increased
levels have been negatively associated with vascular calcifications [19,20], vascular smooth
muscle cell (VSMC) apoptosis [19], and EC oxidative stress [21] and apoptosis [22]. CaP
materials degrade via solution-, protein-, and cell-mediated mechanisms, resulting in the ionic
transfer of calcium and inorganic phosphate from the solid to the liquid phase [23]. Further
research will be necessary to determine whether a local excess of CaP degradation products
aids or negatively influences revascularization within the bone-healing environment as well as to
elucidate possible systemic effects.
In addition to the chemical changes induced by CaP degradation, the mechanical and physical
aspects of introducing CaPs also need to be considered. Both ECs and VSMCs are known to
respond to mechanical stretching that induces gene expression and protein synthesis through
mechanoreceptors such as stretch-activated channels, integrin proteins, and CD31 [24];
whether they also respond to strains imposed on CaP remains to be determined. Computational
modeling has described the effects of CaP strain on angiogenesis [25], but CaP-induced
changes on tissue stiffness have not been deeply investigated in relation to angiogenesis.
Physical features of CaP materials, such as porosity, also influence new vessel formation:
interconnected pore sizes have been reported to be beneficial in the range of 100–150 mm
[26,27] or even larger depending on the vessel diameter [28], while macropores in the range of
300–400 mm have been often reported to be favorable [29]. Furthermore, the specific phase of
the CaP can also impact on angiogenesis [30]. Importantly, these physical features relate to the
mechanical properties and degradation rate of the material. Because the load-bearing capabili-
ties of CaPs are often mentioned as a limitation [31], the balance between multiple mechanical
and physical properties is an important consideration for future CaP design.Trends in Biotechnology, December 2016, Vol. 34, No. 12 985
Angiogenic Possibilities with CaPs
Many strategies have been investigated for adding various biological and synthetic agents with
cell-signaling capabilities, including soaking, encapsulation, or covalent bonding of growth
factors [32]. These strategies for CaPs have been previously reviewed in an osteogenic context
[6]. We focus here on methods to specifically address angiogenesis with CaP use.
Biological Options
Autologous growth factors, those sequestered from one's own body, contain proangiogenic
factors such as vascular endothelial growth factor (VEGF) and basic fibroblast growth factor
(bFGF). Autologous platelet-rich plasma combined with CaP granules was shown to improve
overall bone healing in vivo [33]. Similarly, fibrin glue added to a CaP cement was reported to
improve revascularization specifically, and here a 1:1 ratio was considered most efficacious
when implanted intramuscularly in rabbits [34]. Fundamentally, this approach recreates normal
bone healing, where platelet degranulation during hematoma formation provides the environ-
ment with a variety of growth factors. However, an issue with this approach is the uncontrolled
delivery of unknown concentrations of growth factors, making reproducibility a concern.
Recombinant growth factors and cell-signaling molecules provide an accessible alternative,
while providing greater dose control than autologous methods. Recombinant proteins, such as
VEGF, are a logical approach to improve vasculature. Recombinant VEGF in combination with
commercially available CaP particles was shown to result in greater new bone volume in a rat
calvarial bone-defect model [35] (Figure 2i).
Because VEGF expression peaks from 10–14 days post-injury [36], one issue commonly
discussed is the burst release of factors used in combination with CaPs, or indeed many
biomaterials. To address this concern, release over weeks is sought, rather than over hours or





















Figure 2. (i) A Greater Number of Vessels (Arrows) Were Reported Within the New Bone that Formed in the Pores of Microparticles (mp) of VEGF-
Loaded CaP Bone-Graft Substitutes. Scale bars represent 50 mm; staining with hematoxylin/eosin; two representative samples are shown. Adapted, with
permission, from Kang et al. [35]. (ii) Vessel formation was induced in a dicalcium phosphate dehydrate implant. The control (A) had limited migration, while loading with
copper at 56 ng (B), 560 ng (C), and 5600 ng (D) gave dose-related improvements. When VEGF only was loaded onto implants at 0.2 mg (E), and 2 mg (F), vessel
formation was even greater, demonstrating the beneficial effect of combining promoters of angiogenesis with CaP implants. Adapted from Barralet et al. [52]. (iii) The CaP-
based scaffold was loaded with MSCs and augmented by inserting a vascular bundle into the side grooves of the scaffold and covering it with a fascia flap. Adapted, with
permission, from Fan et al. [64].
986 Trends in Biotechnology, December 2016, Vol. 34, No. 12
b-tricalcium phosphate (b-TCP), was reported to benefit vascularization in cranial bone defects
in mice, which was attributed to more sustained VEGF release [37], and reiterates the need to
align the release kinetics with the needs of the environment. Other growth factors and combi-
nations have also been successfully implemented with CaPs. In combination with a BCP, bFGF
upregulated the expression of markers of osteogenic differentiation of mesenchymal stem cells
(MSCs) in vitro [38]. In an in vivo study, the combination of bFGF, bone morphogenetic protein 2
(BMP-2), mesenchymal stem cells (MSCs), and hydroxyapatite particles was more efficacious
than MSCs with hydroxyapatite for fusing spinal vertebrae in rabbits [39]. Similarly, recombinant
VEGF combined with BMP-2 loaded onto a CaP scaffold was also shown to act synergistically in
calvarial bone defects in nude mice, with VEGF possibly also playing a chemotactic role for the
osteoprogenitors needed for BMP-2 to exert its osteoinductive effect [40]. Despite positive
results with proangiogenic growth factors, angiogenic processes are often overlooked, making it
difficult to elucidate the exact mechanisms and timelines without an understanding of the
preceding vascularization. This insight is especially important in studies utilizing bFGF and/or
VEGF. While downsides may include the costs and concerns with safety, adding proangiogenic
growth factors to CaP-based biomaterials is relatively achievable and appears efficacious.
However, more understanding is needed on how to combine these growth factors effectively
with CaPs, and deeper investigation is needed into in vivo endpoints to assess successful
vascularization.
In addition to using growth factors, prevascularization has been considered as another promis-
ing method. In this case vessels are formed in vitro before implantation through coculturing of
MSCs and ECs to form cell aggregates [41], as well as in combination with endothelial-induced
MSCs within a hydrogel [42] or a collagen-based material [43]. While a promising strategy, this
approach is less commonly applied to CaPs. When ECs were combined with either hydroxy-
apatite or b-TCP, both of the CaPs supported a microcapillary-like network of ECs upon
angiogenic stimulation in vitro [44], and this demonstrated feasibility of combining ECs with
CaPs. Similarly, a coculture of HUVECs and osteoblasts on CaP cement was reported to
sufficiently prevascularize CaP scaffolds in vitro [45,46]. In another example, exogenous sonic
hedgehog combined with osteoinductive CaP granules was implanted subcutaneously in mice
and was reported to induce in vitro vessel formation, displaying anastomoses with the host
vasculature and subsequently more mature bone formation [47]. While prevascularization in vitro
is an interesting approach, the cell source and anastomoses to the host vessels remain issues to
address [48]. This successful connection to the existing vasculature appears to be the greatest
challenge limiting the translation of this approach, regardless of the bone-graft-substitute
material.
Synthetic and Manufactured Options
While autologous and exogenous growth factors are promising, synthetic options are an
encouraging alternative, especially to limit costs and safety concerns. The inorganic portion
of bone is a CaP-based mineral that contains a variety of trace elements [49]. These same
inorganic elements, or bioinorganics, have been introduced as additives to CaPs and were
shown to be capable of stimulating many bone-related, cellular signaling mechanisms [50].
Strontium, while often considered a promoter of osteogenesis, has been linked to the increase in
proangiogenic factors from possibly osteoblasts [51], indirectly promoting vascularization.
Copper, also a bioinorganic, appears to have direct proangiogenic potential. Copper sulfate
adsorbed onto a 3D-printed, CaP-cement scaffold was reported to improve angiogenesis over
controls within the peritoneal cavity in mice, and showed even greater improvement when used
in combination with exogenous VEGF [52] (Figure 2ii). Similarly, cobalt incorporated into CaP
coatings has been previously suggested to have the potential to stimulate angiogenesis [53].
However, incorporation of copper and cobalt together in CaPs was shown to reduce osteoblast
proliferation and alkaline phosphatase (ALP) expression in vitro [54], as well as human MSCTrends in Biotechnology, December 2016, Vol. 34, No. 12 987
osteogenic gene expression, indicating that positive gains in angiogenesis can negatively impact
on osteogenic processes. Some of these losses may be recovered in vitro using combined
strategies with pro-osteogenic bioinorganics [55]. In addition, the presence of such inorganic
additives within the crystal structure of the CaP modifies the structure and, in turn, the dissolution
rate of the material [23]. This changes the availability of both the added ion, and the calcium and
inorganic phosphate ions, making it even more difficult to appreciate the local ion concentrations
between materials. Overall, the incorporation of bioinorganics into CaPs is a relatively cheap
alternative with proven potential. Future developments of bioinorganic additives should consider
issues of toxicity as well as systemic accumulation and its effects.
Besides the addition of bioinorganics, combining different materials with CaPs has also been
shown as a successful synthetic strategy to improve the process of new blood vessel formation.
Using an osteoblast and EC coculture system, a polymer and ceramic composite was found to
have benefits for EC growth and vessel-like formation in vitro. A higher polymer ratio supported
early angiogenesis and, importantly, was not reported to adversely affect osteogenic processes
[56]. Similarly, CaP nanoparticles at 20% w/w within electrospun poly(lactic acid) upregulated
VEGF expression in ECs in vitro and supported vessel formation when implanted subcutaneously
in mice, suggesting a positive angiogenic effect from the composite material. Further, a composite
of CaP housed within a polymer scaffold was reported to favor angiogenesis over the polymer
alone, possibly via the chemotaxis and polarization of M1- and M2-phenotype macrophages [57].
Composite CaP polymers have been suggested to improve the mechanical properties and
degradation kinetics [31] and, combined with potential improvements in angiogenesis, such
composites may be useful overall. Refining the combinations and ratios and obtaining greater
mechanistic insight will be necessary to further develop such composite materials.
A third synthetic strategy to stimulate angiogenesis involves the creation of a hypoxic environ-
ment (Box 3). This beneficial effect has been demonstrated with small-molecule hypoxia
mimickers, such as phenanthroline, to induce blood vessel formation within Matrigel plugs
implanted subcutaneously in mice [58]. However, few studies have used this strategy in
combination with CaPs for bone-regeneration applications. Cobalt is thought to act as a
hypoxia-mimicker: in combination with a mesoporous bioactive glass, a low percentage of
cobalt ions demonstrated increased hypoxia-inducible factor (HIF)-1/ in vitro [59]. However, the
calcium quantities of such glass scaffolds are very different compared to CaPs. In addition,
because hypoxic conditions are thought to modulate chondrogenesis via HIF activity in devel-
oping limbs [60], inducing hypoxic conditions within bone-healing environments may promote
the chondrogenic differentiation of recruited MSCs rather than their osteogenic differentiation.
Combination strategies with CaPs and hypoxia mimickers are lacking. A potential strategy for
larger bone defects may be to combine CaPs, hypoxia mimickers, and either chemotactic
agents or cell delivery.Box 3. Hypoxia and Its Role
A major role of blood vessels throughout the body is to supply oxygen to cells. Normoxic conditions are within the range
of 2–9% oxygen [60]; a lack of blood vessels limits oxygen supply, inducing hypoxic conditions within the microenviron-
ment. Blood vessels are only considered useful to cells within a maximum range of 100–200 mm, the oxygen diffusion
limit. Interestingly, the oxygen limit is itself a strong driver for angiogenesis, in which transcription factors such as hypoxia-
inducible factors (HIF) regulate many pro- and antiangiogenic factors [78,89]. This hypoxic mechanism controls
angiogenesis via the upregulation of VEGF-A [80]. Enhanced HIF-1/ has been related to the increase in osteoprogenitors
and subsequent bone formation [81]. During early healing, inflammatory processes encourage bFGF release from
macrophages when the oxygen tension is low and lactate is high from anaerobic metabolism [90]. This release, combined
with increased angiogenic activity during fibrin or foreign material phagocytosis, contributes to revascularization [86].
Even with evidence of revascularization, the time taken to achieve the appropriate vasculature and any non-uniformity in
the distribution of molecules, factors, and cells can contribute to unfavorable overall conditions and outcomes [91].
Because a lack of oxygen and blood supply can result in inadequate bone healing, unaided standard hypoxia-induced
mechanisms may not be successful on their own.
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Surgical and In Situ Options
In addition to the aforementioned strategies that focus on modifications and additives to CaP
bone-graft substitutes, numerous options exist to stimulate angiogenesis during surgery or
inside the body. For example, by accessing the already functioning vasculature, free flap and
muscle coverage can promote bone healing. In worst-case scenarios, such as when the
periosteum tissue is also compromised, applying revascularization methods are even more
important [61]. Another approach is to use a degradable bone-graft substitute as a graft
extender, combined with a vascularized autograft [62] as a means to deliver vascular structures
to a defect site. Alternatively, utilizing the local functioning vasculature is also possible. Arterio-
venous vascular bundles placed in the grooves of a nano-hydroxyapatite-based material in rats
improved vascularization compared to the material alone, with a corresponding upregulation of
VEGF-C and bFGF [63]. Similarly, when combined with MSCs, this approach was shown to
improve vascularization within bone defects of rhesus monkeys, further improved with a fascia
flap surrounding the CaP [64] (Figure 2iii). In a medial thigh rat model using a BCP, the
importance of both the intrinsic and extrinsic angiogenesis was demonstrated, where approxi-
mately 80% of the vessels were connected to the arteriovenous bundle after 2 weeks, increasing
to 97% at 8 weeks [65]. While this approach is relevant and accessible, the relationship between
vascularization, CaP degradation, and bone formation has not been well studied. In an intra-
muscular ectopic bone model in dogs, the higher flow rate of the arteriovenous bundle was
shown to increase the sprouting of vessels over a ligated vascular bundle. However, this
condition also corresponded with an increased CaP degradation rate, which resulted in less
bone formation at 6 months than in the group with the ligated bundle [66]. Overall, surgical
revascularization is an option that can be readily incorporated with CaP use. As a caveat to the
benefits, the rate of failure due to thrombosis or other causes can be an issue [67]. In addition,
further studies will be necessary to evaluate surgical strategies in comparison with biological or
synthetic approaches.
Mechanical stimulation is another interesting in situ strategy for angiogenesis during bone
healing. Indeed, a well-known aspect of healing is the response to mechanical stability and
forces on bone formation. Wolff's law proposes that bone adapts and remodels according to
mechanical stimuli, with osteocytes being mainly responsible for sensing external loads.
Mechanotaxis – cell migration induced by changes in the mechanical environment – is well
known to play a role in EC behavior via internal or external interactions via cytoskeletal protein
filaments [68]. Vessels form preferentially from regions of higher deformation in vitro [69],
although VEGF signaling was also reported to not be affected by either cyclic strains in vitro
[70] or instability in a mouse tibial bone-fracture model [71]. This suggests the role of other
mechanisms, such as those from angiopoietins that mediate endothelial cell–cell interactions,
PDGF-bb involved in VSMC chemotaxis [70], and regulators such as Rho GTPases that can
influence cell contraction [72]. In an unvalidated computational model simulating CaP use and
cyclic strain, no difference in angiogenesis was calculated between 0.5% to 1% strain, while
changes were confirmed in the osteoblast, chondrocyte, and fibroblast ratios, as well as
increasing tissue stiffness over time [25]. Overall, while the mechanical aspects of osteogenesis
and angiogenesis are very relevant to bone healing, there is a lack of information about whether
externally applied mechanical stimulation within a CaP-augmented bone-healing site promotes
vessel formation.
Other modes of stimulation, such as ultrasound or electromagnetic fields, have shown positive
results for bone regeneration. Low-intensity pulsed ultrasound (LIPUS) has demonstrated an
improved time to osteoporotic callus bridging in femoral fractures in rats, with increased VEGF
expression [73]. When used with a b-TCP, the combination with LIPUS and MSCs improved
spinal fusion in rabbits [74], indicating the benefits of combined approaches. With similar results,
electrical stimulation and the generation of an electromagnetic field across a defect site haveTrends in Biotechnology, December 2016, Vol. 34, No. 12 989
Outstanding Questions
Is optimizing the physicochemical,
structural, and mechanical properties
of CaPs a sufficiently strong tool to
stimulate angiogenesis without the
need for additives?
Will inorganic compounds or small mol-
ecules be sufficient to replace biologi-
cal approaches in stimulating
angiogenesis in CaPs?
What are the underlying mechanisms
behind the effects of individual proper-
ties of (functionalized) CaPs on angio-
genesis and bone formation, and how
can they be better employed to opti-
mize the clinical performance of CaPs?
How can in vitro models encompass
more aspects of bone healing, includ-
ing angiogenesis, to accelerate CaP
bone-graft substitute research?
Will the strategies to address both
bone formation and angiogenesis/vas-
cularization in CaPs lead to synthetic
bone graft substitutes that can fully
replace autografts?been shown to improve CaP osseointegration in the femoral cortical bone of rabbits [75]. In
terms of angiogenesis, electromagnetic stimulation was shown to increase EC proliferation and
tube-like formation. This positive effect on angiogenesis was even suggested to be the driver of
the positive effects found within bone-healing studies, as opposed to having a direct effect on
osteogenesis [76], although there is a lack of recent studies confirming this. Both ultrasound and
electromagnetic stimulation have historically positive results for bone healing, even in combina-
tion with CaPs, as the above studies demonstrate. While combination strategies have been
understudied, there appears to be no reason for any detrimental effect on angiogenesis when
combining stimulation with CaPs.
Conclusions and Future Outlook
CaPs in themselves seem to have the potential to influence angiogenesis. Nonetheless, current
data are limited to explain the extent of this influence, and how it compares to other stimulatory
and inhibitory mechanisms. Regardless, the positive results from various strategies combined
with CaPs (Figure 3) demonstrate clear potential and call for further research and improvements
(see Outstanding Questions). Implant design, proangiogenic factor delivery, and prevasculari-
zation are the major directions evolving to address the issue of vasculature. For these, many
challenges still need to be overcome. The inclusion of ions, molecules, or growth factors requires
better temporal control of their release, which could allow greater control of the bone-healing
mechanisms. The benefits of completely synthetic approaches are that they do not rely on
exogenous or recombinant factors and do not require the harvesting or in vitro culturing of cells.
However, recurring concerns about the toxicity of additives need to be further considered. In
addition, immunomodulation, such as macrophage polarization, may prove worthwhile to
explore [77], although further research will be necessary to confirm the direct connection
between CaPs, immunomodulation, and revascularization. Lastly, in vitro prevascularization
needs to address issues related to associated cell death and failures in connecting to the host
system [48,78]. Taken together, CaPs have clear benefits for osteogenic processes and have
shown positive results for bone healing in general. To advance this material further, concerted
efforts must be devoted to study the effects of CaP materials, and almost all bone-graft
substitutes, on angiogenic responses.Synthec/Manufactured












Surgical revascularizaon (vascular bundles)
Smulaon (mechanical, ultrasound, electromagnec)
Figure 3. Multiple Options To Address Angiogenesis Using CaP Bone-Graft Substitutes. Vascularization (red
vessels) within CaP (grey granule) can be stimulated by modifications to the material itself (black text) or by complementary
approaches (red text). *Hypoxia mimickers can also be biological.
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